The Effect of Antiestrogen Agents on Risk of Autoimmune Disorders in Patients with Breast Cancer

REFERENCES

1. 1.↵
   1. O’Neill S,
   2. Cervera R

   . Systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2010;24:841–55.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Carmona L,
   2. Cross M,
   3. Williams B,
   4. Lassere M,
   5. March L

   . Rheumatoid arthritis. Best Pract Res Clin Rheumatol 2010; 24:733–45.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Tedeschi SK,
   2. Bermas B,
   3. Costenbader KH

   . Sexual disparities in the incidence and course of SLE and RA. Clin Immunol 2013; 149:211–8.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Fairweather D,
   2. Frisancho-Kiss S,
   3. Rose NR

   . Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 2008;173:600–9.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Wilson KB,
   2. Evans M,
   3. Abdou NI

   . Presence of a variant form of the estrogen receptor in peripheral blood mononuclear cells from normal individuals and lupus patients. J Reprod Immunol 1996;31:199–208.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Ishizuka M,
   2. Hatori M,
   3. Suzuki T,
   4. Miki Y,
   5. Darnel AD,
   6. Tazawa C,
   7. et al.

   Sex steroid receptors in rheumatoid arthritis. Clin Sci 2004;106:293–300.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Wang J,
   2. Nuite M,
   3. McAlindon TE

   . Association of estrogen and aromatase gene polymorphisms with systemic lupus erythematosus. Lupus 2010;19:734–40.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Capellino S,
   2. Riepl B,
   3. Rauch L,
   4. Angele P,
   5. Cutolo M,
   6. Straub RH

   . Quantitative determination of steroid hormone receptor positive cells in the synovium of patients with rheumatoid arthritis and osteoarthritis: is there a link to inflammation? Ann Rheum Dis 2007;66:53–8.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Sthoeger ZM,
   2. Zinger H,
   3. Mozes E

   . Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis 2003;62:341–6.

   OpenUrlAbstract/FREE Full Text
10. 10.↵
    1. Roman-Blas JA,
    2. Castañeda S,
    3. Cutolo M,
    4. Herrero-Beaumont G

    . Efficacy and safety of a selective estrogen receptor β agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study. Arthritis Care Res 2010;62:1588–93.

    OpenUrlCrossRef
11. 11.↵
    1. Mok CC,
    2. Ying SKY,
    3. Ma KM,
    4. Wong CK

    . Effect of raloxifene on disease activity and vascular biomarkers in patients with systemic lupus erythematosus: subgroup analysis of a double-blind randomized controlled trial. Lupus 2013;22:1470–8.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Kaelber DC,
    2. Foster W,
    3. Gilder J,
    4. Love TE,
    5. Jain AK

    . Patient characteristics associated with venous thromboembolic events: a cohort study using pooled electronic health record data. J Am Med Inform Assoc 2012;19:965–72.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. International Agency for Research on Cancer, World Health Organization

    . GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. [Internet. Accessed September 9, 2014]. Available from: http://globocan.iarc.fr/Default.aspx
14. 14.↵
    1. Singer O,
    2. Cigler T,
    3. Moore AB,
    4. Levine AB,
    5. Hentel K,
    6. Belfi L,
    7. et al.

    Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study. Arthritis Care Res 2012;64:1910–8.

    OpenUrlCrossRef
15. 15.↵
    1. Komm BS,
    2. Mirkin S

    . An overview of current and emerging SERMs. J Steroid Biochem Mol Biol 2014;143C:207–22.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Dahlman-Wright K,
    2. Cavailles V,
    3. Fuqua SA,
    4. Jordan VC,
    5. Katzenellenbogen JA,
    6. Korach KS,
    7. et al.

    International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol Rev 2006;58:773–81.

    OpenUrlFREE Full Text